(Q26785746)

1

0 references

Marie Kostine

2

0 references

Thomas Barnetche

3

0 references

Marie-Elise Truchetet

Creative Commons Attribution 4.0 International

4

0 references

language of work or name

English

0 references

publication date

4 September 2015

9 references

3 April 2019

18 June 2019

19 June 2019

31 July 2019

15 December 2019

14 September 2020

29 October 2020

8 February 2021

17 October 2022

9 references

3 April 2019

18 June 2019

19 June 2019

31 July 2019

15 December 2019

14 September 2020

29 October 2020

8 February 2021

17 October 2022

13

0 references

issue

1

0 references

page(s)

211

0 references

copyright license

9 references

3 April 2019

18 June 2019

19 June 2019

31 July 2019

15 December 2019

14 September 2020

29 October 2020

8 February 2021

on focus list of Wikimedia project

17 October 2022

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Immunotherapy: past, present and future

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Has the microbiota played a critical role in the evolution of the adaptive immune system?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

The blockade of immune checkpoints in cancer immunotherapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Genetic basis for clinical response to CTLA-4 blockade in melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Identification and management of toxicities from immune checkpoint-blocking drugs

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab-induced hepatitis on 18F-FDG PET/CT in a patient with malignant melanoma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Serious haematological toxicity during and after ipilimumab treatment: a case series.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab in patients with cancer and the management of dermatologic adverse events

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Kidney injuries related to ipilimumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Multifocal radiculoneuropathy during ipilimumab treatment of melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Autoimmunity and treatment outcome in melanoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

The role of CTLA-4 in the regulation of T cell immune responses.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab in patients with melanoma and autoimmune disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Humanized mice as a model for aberrant responses in human T cell immunotherapy.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Melanoma-associated retinopathy treated with ipilimumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Ipilimumab-induced hypophysitis: MR imaging findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Atypical clinical response patterns to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Ipilimumab-induced perforating colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Lymphocytic colitis secondary to ipilimumab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Ipilimumab-induced acute severe colitis treated by infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Ipilimumab-associated colitis: CT findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Association between ipilimumab and celiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Orbital myositis associated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET/CT interpretation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Pulmonary sarcoid-like granulomatosis induced by ipilimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Organizing pneumonia as a side effect of ipilimumab treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Hemophilia A induced by ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Transient hypophysitis after cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Anti-CTLA4 antibody-induced lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Hyponatremia associated with Ipilimumab-induced hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Neurological immune-related adverse events of ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Severe meningo-radiculo-neuritis associated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

A case report of orbital inflammatory syndrome secondary to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Ipilimumab immune-related adverse reactions: a case report

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Case of the month. Autoimmune colitis secondary to CTLA-4 blockade

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Autoimmune inflammatory myopathy after treatment with ipilimumab

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4559965

Severe colitis while responding to ipilimumab in metastatic melanoma

28 November 2018

1 reference

12 December 2020

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission

1 reference

12 December 2020

Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma

1 reference

12 December 2020

Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma

1 reference

12 December 2020

Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment

1 reference

12 December 2020

First report of ipilimumab-induced Grover disease

1 reference

12 December 2020

Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma - simultaneous occurrence of pyoderma gangrenosum and colitis

1 reference

12 December 2020

Ipilimumab-induced colitis on FDG PET/CT

1 reference

12 December 2020

Ipilimumab-induced immune-related renal failure--a case report.

1 reference

12 December 2020

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

1 reference

12 December 2020

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

1 reference

12 December 2020

Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy

1 reference

12 December 2020

Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma

1 reference

12 December 2020

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1186%2FS12916-015-0455-8

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1186/S12916-015-0455-8

1 reference

Dimensions Publication ID

1007367199

0 references

Fatcat ID

release_wk2z2gjqtrgbdd6ahl7uxakm6i

0 references

1 reference

1 reference

PubMed publication ID

26337719

1 reference